mechanistic insights and perspectives
Front Clin Diabetes Healthc. 2023 Sep 26:4:1243530.
Abstract Sodium glucose cotransporter 2 inhibitors (SGLT2) have been increasingly pursued as a promising target for addressing residual cardiovascular risk. Prior trials demonstrated that SGLT2i not only promotes glucose-lowering, but also improves endothelial dysfunction, adiposity, fluid overload, and insulin sensitivity thus contributing to hemodynamic changes implicated in its cardiorenal benefits. The mechanisms in the effect of SGLT2i on blood pressure and their potential role in preventing cardiovascular events are hereby revised.
Keywords: SGLT2i; cardiovascular risk; dapagliflozin; empagliflozin; residual risk.
Copyright © 2023 Barreto, Campos-Staffico, Nadruz, Quinaglia and Sposito.
Read Full-Text: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10562622/